Codon Devices Opens European Headquarters

Codon Devices, Inc., the Constructive Biology Company(TM), today
announced its expansion into Europe with the formation of Codon
Devices U.K. Ltd., and the appointment of Michael Dyson, PhD, to the
newly-created position of European Managing Director.

"We are excited to open our new European headquarters as a major
step in our global expansion plans," said John P. Danner, President
and Chief Executive Officer of Codon Devices. "As we industrialize
synthetic biology and drive a new paradigm in research called
Constructive Biology(TM), we are experiencing rapid adoption of our
advanced gene synthesis and protein engineering offerings. The
interest from the European marketplace is tremendous and we are
looking forward to serving these customers more effectively through
this new base of operations."

Michael Dyson will lead Codon Devices U.K., Ltd., reporting to
Michael J. Fitzpatrick, Vice President, Global Sales, Codon Devices,
Inc. Dr. Dyson has more than 20 years of experience leading European
customer service and sales organizations in the life sciences
industry. Prior to joining Codon Devices, Dr. Dyson was Managing
Director for Sequenom, GmbH and Director, European Sales and Marketing
for MicroCal, LLC.

"Mike brings exceptional leadership capability and in-depth
knowledge of the European market," said Michael Fitzpatrick. "His
proven track record of building successful operations to drive growth
and customer satisfaction make him a valuable addition to our team."

"Codon Devices has established strong relationships with many
European pharmaceutical, biotechnology and agribusiness-focused
companies, as well as renowned centers of academic research," said
Michael Dyson. "I am excited to build upon Codon's strong position in
the market through this new headquarters and the rapid installation of
direct sales operations throughout Europe."

About Codon Devices

Codon Devices, Inc., based in Cambridge, MA, is a privately-held
biotechnology company focused on enabling commercial applications of
synthetic biology. Codon Devices' proprietary synthesis and design
technologies improve the productivity of its industrial,
pharmaceutical and academic customers in a paradigm shift to what the
Company calls Constructive Biology(TM). The Company's focus is on
developing and delivering high-value products and design services in a
variety of application areas, including engineered gene libraries,
engineered cells that produce novel pharmaceuticals, improved
vaccines, agricultural products, and biorefineries for the production
of industrial chemicals and energy. Codon Devices' BioFAB(TM)
Production Platform uses sophisticated informatics, robotics and
sequencing technologies to accurately synthesize genetic codes orders
of magnitude more rapidly and cost-effectively than other currently
available technology. More information about Codon Devices is
available at www.codondevices.com.